Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 135
- 试验地点
- 1
- 主要终点
- arrhythmogenic cardiac effects of BTKi and sudden death within the first 12 months of BTKi therapy
研究概览
简要总结
Background:
Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death. In this natural history study, researchers want to learn how BTKi affects the heart.
Objective:
To identify and monitor the effects of BTKi on the heart.
Eligibility:
People aged 18 and older currently receiving or planning to receive BTKi or venetoclax.
Design:
Participants who have not yet started BTKi will have 2 required clinic visits: 1 before they start taking BTKi, and 1 about 6 months later. Participants who are already taking BTKi will have 1 required visit.
Participants will undergo multiple tests:
A physical exam, including collection of blood and saliva.
A test that measures heart activity via stickers placed on the chest.
A test that uses sound waves to capture images of the heart.
An exercise stress test that monitors heart activity and blood pressure while the participant works on a treadmill or stationary bike. Sound wave images of the heart may also be taken while the participant exercises.
Stress magnetic resonance imaging (MRI) may be done in place of an exercise test. Participants will lie on a table that slides into a tube. They will be given drugs to stress the heart while images are taken.
Participants may wear a device to monitor their heart at home.
Participants may have repeat visits if they develop heart symptoms or if they need to stop taking BTKi. They will have follow-up phone calls each year for up to 3 years.
详细描述
Study Description:
Pharmacologic therapy with BTK inhibitors (BTKi) is associated with an increased risk of cardiac arrhythmias which can lead to sudden death. There is currently no standard for cardiac screening or monitoring patients on BTKi. We hypothesize that thorough and routine comprehensive cardiac evaluations prior to starting therapy with BTKi and repeated during therapy with BTKi will result in earlier identification of cardiac arrhythmias with the goal of minimizing associated morbidity and mortality. In addition, venetoclax, a different standard therapy for chronic lymphocytic leukemia, has not been associated with increased cardiac adverse events and could serve as a control group.
Objectives:
Primary objective: Identify, monitor, and analyze the arrhythmogenic effects of BTKi as well as sudden death
Secondary objective: Assess the utility of different cardiac tests for identifying and monitoring cardiac arrhythmias in patients receiving BTKi or venetoclax
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 110 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •INCLUSION CRITERIA:
- •To be eligible to participate in this study, an individual must meet all of the following criteria:
- •Currently receiving or planning to receive a BTKi or venetoclax.
- •Male or female, aged 18 or older
- •Stated willingness to comply with all study procedures and availability for the duration of the study
- •Ability of subject to understand and the willingness to sign a written informed consent document
排除标准
- •An individual who meets any of the following criteria will be excluded from participation in this study:
- •Any acute cardiac condition including myocardial infarction or decompensated heart failure within the past 3 months
- •Pregnancy or lactation- use of BTK inhibitors is contraindicated in pregnant or nursing individuals.
研究组 & 干预措施
Cohort B
includes all patients already on therapy with a BTKi
Cohort C
includes all patients prior to starting therapy with venetoclax
Cohort A
includes all patients prior to starting therapy with a BTKi
结局指标
主要结局
arrhythmogenic cardiac effects of BTKi and sudden death within the first 12 months of BTKi therapy
时间窗: 12 months
1\. Clinically significant cardiac arrhythmias while on a BTKi (treatment emergent in those without a history of arrhythmias and worsening of arrhythmia for those with an arrhythmia at the time of enrollment testing) within 12 months. For Cohort A, if a patient has an arrhythmia at the time of baseline testing, only worsening or new arrhythmias will be called an event. For Cohort B, all arrhythmias will be called an event. 2. Sudden death
次要结局
- tests for identifying and monitoring cardiac arrhythmias in patients receiving BTKi(36 months)